On the morning of June 15, the Spanish pharmaceutical company Hipra signed an agreement with CMC to invest no less than EUR 50 million in an iconic animal health product R&D and production base in the Asia-Pacific region.
This marks the settlement of another famous multinational pharmaceutical enterprise in CMC after the establishment of Fuhong Kanghe Pharmaceutical Jiangsu Co., Ltd. on June 8 by Shanghai Fosun Pharmaceutical, a well-known domestic pharmaceutical enterprise, and Marubeni Corporation, a Fortune Global 500 company in Japan. CMC officially welcomes its 12th renowned multinational pharmaceutical enterprise.
Hipra, based in Spain, is one of the top five animal health enterprises in the world, specializing in the research and production of veterinary biological products and diagnostic reagents, and providing cutting-edge technology such as antibiotic-free aquaculture. It has sales companies and production bases in 27 countries around the world.